Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading to microangiopathic hemolytic anemia, platelet consumpti...

Descripción completa

Detalles Bibliográficos
Autores principales: Moscvin, Maria, Liacos, Christine Ivy, Chen, Tianzeng, Theodorakakou, Foteini, Fotiou, Despina, Hossain, Shahrier, Rowell, Sean, Leblebjian, Houry, Regan, Eileen, Czarnecki, Peter, Bagnoli, Filippo, Bolli, Niccolo’, Richardson, Paul, Rennke, Helmut G., Dimopoulos, Meletios A., Kastritis, Efstathios, Bianchi, Giada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971259/
https://www.ncbi.nlm.nih.gov/pubmed/36849497
http://dx.doi.org/10.1038/s41408-023-00802-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971259/
https://www.ncbi.nlm.nih.gov/pubmed/36849497
http://dx.doi.org/10.1038/s41408-023-00802-0

Ejemplares similares